BMS-986308

BMS-986308 is a novel, orally active, selective inhibitor of the renal outer medullary potassium channel (ROMK) (also known as Kir1.1 or KCNJ1). It was developed by Bristol Myers Squibb as a potential potassium-sparing diuretic for the treatment of heart failure and related conditions characterized by fluid overload and electrolyte imbalance. The drug acts as a reversible antagonist of ROMK, leading to robust potassium-sparing diuretic and natriuretic effects in preclinical models. BMS-986308 has demonstrated high selectivity for ROMK over other inwardly rectifying potassium channels and favorable pharmacokinetic properties in both preclinical and early clinical studies[1][2][3][5][8]. Clinical trials have focused on evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers[4][6].